Acadia Pharmaceuticals Inc. (ACAD)
Health Care ยท Pharmaceutical Preparations
Acadia Pharmaceuticals Inc. (ACAD) is listed on Nasdaq, where its shares have traded since May 27, 2004. SentiSense covers Acadia Pharmaceuticals Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Catherine Owen Adams is its chief executive officer. The company reports 798 employees, and its corporate website is www.acadia.com.
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Latest reported results
Acadia Pharmaceuticals Inc. reported revenue of $342.3 million for Q3 FY2026, up 22.8% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 342 institutions reported holding ACAD, with 168.5 million shares worth $4.3 billion in aggregate. The largest reported holders were Baker Bros. Advisors, BlackRock and Vanguard.
More on ACAD
- ACAD sentiment: whether news and social coverage of Acadia Pharmaceuticals Inc. leans bullish or bearish, and the stories driving it.
- ACAD ownership: all 342 reporting institutions, plus insider and congressional trades.
- ACAD financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
Frequently asked questions
What does Acadia Pharmaceuticals Inc. do?
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world.
What sector is ACAD in?
SentiSense classifies Acadia Pharmaceuticals Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does ACAD stock trade?
Acadia Pharmaceuticals Inc. (ACAD) is listed on Nasdaq, where its shares have traded since May 27, 2004.
Who is the CEO of Acadia Pharmaceuticals Inc.?
Catherine Owen Adams is the chief executive officer of Acadia Pharmaceuticals Inc..